Ezutromid is primarily investigated for its potential therapeutic applications in treating Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration. It functions as a utrophin modulator and histone deacetylase (HDAC) inhibitor, aiming to upregulate the expression of utrophin, a protein that can compensate for the lack of dystrophin in DMD patients. By enhancing utrophin levels, it may help stabilize muscle fibers and slow disease progression. Clinical trials have explored its efficacy in improving muscle function and reducing inflammation in affected individuals. Its development represents a promising approach to address the underlying cause of DMD, offering hope for a disease-modifying treatment.